SANDOSTATIN LAR Drug Patent Profile
✉ Email this page to a colleague
When do Sandostatin Lar patents expire, and when can generic versions of Sandostatin Lar launch?
Sandostatin Lar is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sandostatin Lar
A generic version of SANDOSTATIN LAR was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.
Summary for SANDOSTATIN LAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 29 |
Clinical Trials: | 76 |
Patent Applications: | 827 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SANDOSTATIN LAR |
DailyMed Link: | SANDOSTATIN LAR at DailyMed |
Recent Clinical Trials for SANDOSTATIN LAR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Belgium Health Care Knowledge Centre | Phase 4 |
University Hospital, Antwerp | Phase 4 |
ZonMw: The Netherlands Organisation for Health Research and Development | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for SANDOSTATIN LAR
US Patents and Regulatory Information for SANDOSTATIN LAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-003 | Nov 25, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SANDOSTATIN LAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-003 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SANDOSTATIN LAR
See the table below for patents covering SANDOSTATIN LAR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Finland | 20000059 | ⤷ Try a Trial | |
Slovakia | 104098 | SUSTAINED DELIVERY OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM | ⤷ Try a Trial |
China | 100493647 | ⤷ Try a Trial | |
Japan | S6351159 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SANDOSTATIN LAR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0029579 | SPC/GB93/097 | United Kingdom | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |